Biogen’s Recombinant Factors for Hemophilia May Provide Breakthrough for Patients

by Elizabeth Krutoholow

 

Biogen’s hemophilia drugs may provide a breakthrough for patients by offering protection against bleeding with fewer infusions than standard agents, Dr. Jerry Powell, a hematologist with the UC Davis Comprehensive Cancer Center said in an interview.

 

These drugs will compete against currently marketed recombinant factors like Baxter’s Advate and Pfizer’s BeneFIX.

 

Read more >>>>

 

Bloomberg BRIEF Newsletters